CN103083322A - Medicinal composition containing injection cefmenoxime hydrochloride and compound amino acid injection - Google Patents
Medicinal composition containing injection cefmenoxime hydrochloride and compound amino acid injection Download PDFInfo
- Publication number
- CN103083322A CN103083322A CN2013100434256A CN201310043425A CN103083322A CN 103083322 A CN103083322 A CN 103083322A CN 2013100434256 A CN2013100434256 A CN 2013100434256A CN 201310043425 A CN201310043425 A CN 201310043425A CN 103083322 A CN103083322 A CN 103083322A
- Authority
- CN
- China
- Prior art keywords
- injection
- amino acid
- hydrochloride
- cefmenoxime hydrochloride
- cefmenoxime
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a medicinal composition containing injection cefmenoxime hydrochloride and a compound amino acid injection, and especially relates to a medicinal composition packaged in a combination manner and comprising injection cefmenoxime hydrochloride and the compound amino acid injection. When the medicinal composition is used, the injection cefmenoxime hydrochloride is added to the compound amino acid injection, and the medicinal composition is intravenously dripped for 30min-2h. Compared with a compatible mixture of the injection cefmenoxime hydrochloride and the compound amino acid injection, the combination packaged medicinal composition allows the steps to be simplifies, the safety to be improved, the stability of cefmenoxime hydrochloride to be large and the clinical application quality and the bioavailability of the medicinal composition to be improved.
Description
Technical field
The present invention relates to the pharmaceutical composition of a kind of cefmenoxime hydrochloride in and Amino Acid Compound Injection, be specifically related to the Combination application packing of the formulated sterile solution for injection of a kind of cefmenoxime hydrochloride in and 18 kinds of crystalline amino acids and xylitol, belong to medical technical field.
Background technology
Abbott 50192 is the semisynthetic cephalosporins broad ectrum antibiotic of the third generation, and the biosynthesis by the anti-bacteria cell wall reaches bactericidal action.It is because it has good epicyte permeability that Abbott 50192 has strong antibacterial action to gram negative bacteria, stable to beta-lactamase, and the affinity to penicillin-binding protein (PBPs) 1A, 1B and 3 is strong, has stronger inhibition thereby cell wall mucopeptide is cross-linked to form.
In vitro tests shows, these product all have effect to gram positive bacteria and negative bacterium.To the antimicrbial power of gram positive bacteria, with micrococcus scarlatinae and streptococcus pneumoniae and opinion, effect is better than cefotiam (CTM) and cefazolin sodium (CEZ).Peptococcus, Peptostreptococcus are shown strong antimicrbial power.To the antimicrbial power of gram-negative bacteria, with escherichia coli and pneumobacillus and opinion slightly is better than CTM, far be better than CEZ.To hemophilus influenza, Proteus, emplastic serratia, the antimicrbial power that citrobacter belongs to, intestinal all belongs to is stronger than CTM, and is strong more than CEZ.In addition Bacteroides is also shown strong antimicrbial power.
Aminoacid for human body synthetic protein and other tissue provide nitrogenous source, is the base substance of keeping the human life.Aminoacid is except providing nitrogenous source for synthetic protein, part can be used as the energy supply material through oxidation Decomposition, another a small amount of aminoacid can also transform and become some biological active substanceies, thereby keeps the function of some tissues and organ, and each seed amino acid can be transported between individual tissue by blood.To guarantee the amino acid metabolism in tissue.Human normal plasma's amino acid concentration is not high, total concentration be about 2 millimoles/liter, children's in cell is lower for the overwhelming majority, may be fast with children growth, aminoacid take in organize more relevant.Therefore, children's should be higher than the adult to the aminoacid intake.
Amino Acid Compound Injection participates in the anabolism of protein in the situation that the Power supply abundance can enter histiocyte, obtain positive nitrogen balance, and generate the biological active substanceies such as enzyme, hormone, antibody, structural protein, and promote organization healing, recover normal physiological function.
Amino Acid Compound Injection is used for that muscle catabolism under the stress state such as large-area burns, wound and severe infections is hyperfunction, the patient's of digestive system function obstacle, nutrition deterioration and immunologic function degression nutritional support, also be used for patients after surgery, improve its nutritional status.Be used for the patient that the aminoacid such as protein Deficiency of Intake, malabsorption can not satisfy the organism metabolism needs.Also be used for improving the nutriture of patients after surgery.
In addition, only mention cefmenoxime hydrochloride in operation instructions dissolves in 0.9% sodium chloride injection or glucose injection to prior art, intravenous drip also can be added on 1 consumption 0.5g-2g of this product in the fluid infusion of sugar liquid, electrolyte solution or amino acid preparation etc., carried out intravenous drip in 30 minutes-2 hours to the adult.Need to buy respectively use in conjunction in clinical use, not cefmenoxime hydrochloride in and Amino Acid Compound Injection assembly packaging appear on market and medical institutions in.
The applicant offers medical institutions and market with cefmenoxime hydrochloride in of the present invention and Amino Acid Compound Injection with the form of assembly packaging, not only greatly improved ease of use and the drug safety of medical institutions, and the stability of each drug alone has been of great benefit to; More importantly by adding xylitol to obtain unforeseeable clinical practice quality and the bioavailability of using simultaneously cefmenoxime hydrochloride in and amino acid injection that improved in Amino Acid Compound Injection.
Summary of the invention
In order to overcome the series of problems that exists in prior art, the inventor has creatively found employing amino acid Xylitol injection and cefmenoxime hydrochloride in compatibility use in conjunction, being about to the formulated sterile solution for injection dissolving of the cefmenoxime hydrochloride in of independent packaging and 18 kinds of crystalline amino acids and xylitol mixes and inputs afterwards in body, the effect that not only has broad-spectrum antiseptic, but also treat simultaneously the amino acids nutritional supplementation.
One of purpose of the present invention, a kind of new Abbott 50192 and the pharmaceutical composition of Amino Acid Compound Injection are provided, wherein, cefmenoxime hydrochloride in is the powder ampoule agent for injection that adds the natrium carbonicum calcinatum mix homogeneously, and Amino Acid Compound Injection is the formulated sterile solution for injection of 18 kinds of crystalline amino acids and xylitol.
One of purpose of the present invention, the Combination application packing of a kind of cefmenoxime hydrochloride in and Amino Acid Compound Injection is provided, wherein, cefmenoxime hydrochloride in is the powder ampoule agent for injection that adds the natrium carbonicum calcinatum mix homogeneously, and Amino Acid Compound Injection is the formulated sterile solution for injection of 18 kinds of crystalline amino acids and xylitol.
Combination application packing provided by the invention, usage is for to be added in the Amino Acid Compound Injection iv drip 30 minutes-2 hours with cefmenoxime hydrochloride in.
More importantly, the xylitol in Amino Acid Compound Injection helps to improve the absorption of Abbott 50192 medicine also unexpectedly, makes it have the effect that postpones absorption, and curative effect is more obvious, and this is innovative point of the present invention place.
Combination application packing specification provided by the invention is that cefmenoxime hydrochloride in is with C
16H
17N
9O
5S
3Meter 0.25-2.0g, Amino Acid Compound Injection 50-1000ml.
Cefmenoxime hydrochloride in of the present invention is made in the aseptic powder packing of natrium carbonicum calcinatum mix homogeneously by Abbott 50192, perhaps adds appropriate excipient lyophilization by Abbott 50192 and makes.
As one of specific embodiment, concrete component and consumption are as follows:
The present invention also provides a kind of preparation method of cefmenoxime hydrochloride in, and concrete steps are:
The sterilized powder of Abbott 50192 and natrium carbonicum calcinatum mix homogeneously is sent between packing (packing post ambient temperature is 18 ℃～26 ℃, relative humidity is below 65%), the debugging racking machine, regulate step number and mix up loading amount, make loading amount reach the scope of regulation, then be sub-packed in low Pyrex control injection bottle made, press plug entirely, roll lid.
Perhaps, after Abbott 50192 and appropriate excipient dissolving, packing, lyophilization, lid is rolled in tamponade.
Amino Acid Compound Injection of the present invention is the formulated sterile water solution of 18 kinds of crystalline amino acids and xylitol, concrete component comprises arginine hydrochloride 2.89g, histidine monohydrochloride 2.46g, leucine 3.79g, isoleucine 1.70g, lysine hydrochloride 3.33g, phenylalanine 2.83g, threonine 1.97g, valine 1.36g, methionine 1.06g, tryptophan 0.39g, glycine 3.24g, alanine 1.88g, proline 1.00g, tyrosine 0.11g, serine 0.67g, cysteine hydrochloride 0.44g, Aspartic Acid 1.15g, glutamic acid 1.97g, sodium sulfite 0.5g, xylitol 50g, water for injection adds to 1000ml.
The present invention also provides a kind of preparation method of Amino Acid Compound Injection, and concrete steps are:
(1) get approximately 60% water for injection of full dose and boil and add appropriate xylitol to make dissolving, then add approximately 0.15%(g/ml) active carbon boiled 20 minutes, return the filter decolouring after 20 minutes filter enter rare filling of joining.
(2) in dilute preparing tank, filter passes into nitrogen after entering xylitol liquid immediately, what add simultaneously other approximately full dose 40% uses 0.15(g/ml again) active carbon boils 20 minutes pretreated water for injection of absorption and the merging of xylitol liquid, opens when cooling water makes amalgamation liquid be cooled to 60 ℃ to begin to feed intake.
(3) first the antioxidant sodium sulfite is divided into halves, a copy of it antioxidant is dropped in amalgamation liquid, then by above-mentioned formula order, each aminoacid is dropped into one by one and make dissolving, should control temperature during to tryptophan approximately can drop into below 50 ℃, aminoacid feeds intake complete, adds another part antioxidant and cysteine hydrochloride.
(4) slowly adding to regulate pH value 5.5-7.0 with about 10% caustic lye of soda, add adding to the full amount of water for injection, add 0.15%(g/ml) active carbon stirs decolouring 20 minutes, circulating filtration 30 minutes.
(5) filter qualified to visible foreign matters after, fill, sealing, sterilization and get final product.
The present invention also provides the Combination application of a kind of cefmenoxime hydrochloride in and Amino Acid Compound Injection to be packaged in the application for preparing in treatment amino acids nutritional supplementation medicine and extensive pedigree antibiotic, has the human body protein of promotion Metabolism of Normal, correct negative nitrogen balance, replenish protein, accelerating wound provides the effect of energy and essential amino acids for body.In addition, this product essential amino acids meets the Vuj-N formula proportion, and non essential amino acid meets Albumin's pattern.The ratio of essential amino acids and non essential amino acid is 1.04:1, and every seed amino acid easily is effectively used to the synthetic of human body protein, and its bioavailability is high.The contained xylitol of this product can enter the cell interior without insulin, and the formation of tool inhibition ketoboidies, saves protein, improves rate of ultilization of amino acid, and promotes the effect that hepatic glycogen is accumulated, and carbohydrate metabolism is had no adverse effect, and has no to cause the metabolic complication.
The specific embodiment
Embodiment 1The preparation of cefmenoxime hydrochloride in
Prescription:
Preparation process:
(1) with Abbott 50192 sterilized powder 250g(with C
16H
17N
9O
5S
3)
2HC1 meter) send between packing (packing post ambient temperature is 18 ℃～26 ℃, and relative humidity is 65% below), debug racking machine, regulate step number and mix up loading amount, make loading amount reach the scope of regulation, then be sub-packed in low Pyrex control injection bottle made, press full plug, roll lid.
(2) with Abbott 50192 sterilized powder 500g(with C
16H
17N
9O
5S
3)
2HC1 meter) send between packing (packing post ambient temperature is 18 ℃～26 ℃, and relative humidity is 65% below), debug racking machine, regulate step number and mix up loading amount, make loading amount reach the scope of regulation, then be sub-packed in low Pyrex control injection bottle made, press full plug, roll lid.
(3) with Abbott 50192 sterilized powder 1000g(with C
16H
17N
9O
5S
3)
2HC1 meter) send between packing (packing post ambient temperature is 18 ℃～26 ℃, and relative humidity is 65% below), debug racking machine, regulate step number and mix up loading amount, make loading amount reach the scope of regulation, then be sub-packed in low Pyrex control injection bottle made, press full plug, roll lid.
(4) with Abbott 50192 sterilized powder 2000g(with C
16H
17N
9O
5S
3)
2HC1 meter) send between packing (packing post ambient temperature is 18 ℃～26 ℃, and relative humidity is 65% below), debug racking machine, regulate step number and mix up loading amount, make loading amount reach the scope of regulation, then be sub-packed in low Pyrex control injection bottle made, press full plug, roll lid.
Embodiment 2The preparation of Amino Acid Compound Injection
Prescription:
Preparation process:
(1) get 60L water for injection and boil and add the 5000g xylitol to make dissolving, then add the 150g active carbon to boil 20 minutes, return the filter decolouring after 20 minutes filter enter rare filling of joining.
(2) in dilute preparing tank, filter passes into nitrogen after entering xylitol liquid immediately, what add simultaneously other 40L boils 20 minutes pretreated water for injection of absorption and the merging of xylitol liquid with the 150g active carbon again, opens when cooling water makes amalgamation liquid be cooled to 60 ℃ to begin to feed intake.
(3) first antioxidant sodium sulfite 50g is divided into halves, a copy of it antioxidant 25g is dropped in amalgamation liquid, then press above-mentioned formula order with arginine hydrochloride 289g, histidine monohydrochloride 246g, leucine 379g, isoleucine 170g, lysine hydrochloride 333g, phenylalanine 283g, threonine 197g, valine 136g, methionine 106g, tryptophan 39g, glycine 324g, alanine 188g, proline 100g, tyrosine 11g, serine 67g, Aspartic Acid 115g, glutamic acid 197g drops into one by one and makes dissolving, should control temperature during to tryptophan approximately can drop into below 50 ℃, aminoacid feeds intake complete, add another part antioxidant 25g and cysteine hydrochloride 44g.
(4) slowly add to regulate pH value 6.3 with about 10% caustic lye of soda, add adding to the full amount of water for injection, add the 150g active carbon to stir decolouring 20 minutes, circulating filtration 30 minutes.
(5) filter qualified to visible foreign matters after, fill, 100ml/ bottle or 250ml/ bottle or 500ml bottle, sealing, 121 ℃ of pressure sterilizings 20 minutes, and get final product.
Embodiment 3The preparation of assembly packaging medicine
Combination 1: cefmenoxime hydrochloride in 0.25g and Amino Acid Compound Injection 100ml.
Combination 2: cefmenoxime hydrochloride in 0.25g and Amino Acid Compound Injection 250ml.
Combination 3: cefmenoxime hydrochloride in 0.25g and Amino Acid Compound Injection 500ml.
Combination 4: cefmenoxime hydrochloride in 0.5g and Amino Acid Compound Injection 100ml.
Combination 5: cefmenoxime hydrochloride in 0.5g and Amino Acid Compound Injection 250ml.
Combination 6: cefmenoxime hydrochloride in 0.5g and Amino Acid Compound Injection 500ml.
Combination 7: cefmenoxime hydrochloride in 1.0g and Amino Acid Compound Injection 100ml.
Combination 8: cefmenoxime hydrochloride in 1.0g and Amino Acid Compound Injection 250ml.
Combination 9: cefmenoxime hydrochloride in 1.0g and Amino Acid Compound Injection 500ml.
Combination 10: cefmenoxime hydrochloride in 2.0g and Amino Acid Compound Injection 100ml.
Combination 11: cefmenoxime hydrochloride in 2.0g and Amino Acid Compound Injection 250ml.
Combination 12: cefmenoxime hydrochloride in 2.0g and Amino Acid Compound Injection 500ml.
Embodiment 4Stability test
In order to verify that in assembly packaging process of clinical application of the present invention, stability to Abbott 50192 is of great benefit to, the cefmenoxime hydrochloride in that we choose embodiment 1 preparation carries out compatibility with following injection to be mixed,
(1) 0.9% sodium chloride injection lot number: 20120801-1 Qingzhou Yaowang Pharmaceutical Co., Ltd.
(2) 5% glucose injection lot numbers: 20121002-5 Qingzhou Yaowang Pharmaceutical Co., Ltd.
(3) Multiple electrolytes injection lot number: 1206003 Kelun Pharm Ind Co., Ltd., Sichuan
(4) the Amino Acid Compound Injection embodiment of the present invention 2 preparations
Then detect mixed liquor in the related substance situation of change of 0,1,2,4,6 hour Abbott 50192, compare, result is as follows:
Conclusion: can be found out by above result of the test, the Amino Acid Compound Injection compatibility of cefmenoxime hydrochloride in and the embodiment of the present invention 2 preparations mixes, related substance increased minimum in 6 hours, illustrate that stability of solution is better than other three kinds of injection far away, so assembly packaging of the present invention stability to Abbott 50192 in clinical use procedure is of great benefit to, and has ensured product quality.
Embodiment 5The mensuration of blood drug level
40 rats are divided into 4 groups at random, wherein the cefmenoxime hydrochloride in of first group of intravenous injection embodiment 1 preparation and the compatibility mixed liquor of commercially available product 0.9% sodium chloride injection (lot number: 20120801-1, Qingzhou Yaowang Pharmaceutical Co., Ltd.); The cefmenoxime hydrochloride in of second group of intravenous injection embodiment 1 preparation and the compatibility mixed liquor of commercially available product 5% glucose injection (lot number: 20121002-5, Qingzhou Yaowang Pharmaceutical Co., Ltd.); The compatibility mixed liquor of the cefmenoxime hydrochloride in of the 3rd group of intravenous injection embodiment 1 preparation and commercially available product Multiple electrolytes injection (lot number: 1206003, Kelun Pharm Ind Co., Ltd., Sichuan); The compatibility mixed liquor of the Amino Acid Compound Injection of the cefmenoxime hydrochloride in of the 4th group of intravenous injection embodiment 1 preparation and embodiment 2 preparations.With 0.5g Abbott 50192 and 100ml injection compatibility, injected dose is the 8ml/kg body weight.Respectively at 0.5h, 1h, 1.5h, 2h, 3h, 6h, 8h and 12h, take a blood sample after administration, blood sample is measured the blood drug level of Abbott 50192 after treatment with the HPLC-MS method.Draw the four assembly 5 intravenous blood drug level of solution and the relation curves of time, be shown in accompanying drawing 1.
As shown in Figure 1, in four assembly 5 solution, the 4th group of solution intravenous injection has the following advantages: the blood drug level peak value of Abbott 50192 is high, release rate in vivo slows down, distribution time extends in the body circulation, has reached improved delayed release effect, and bioavailability increases.
Embodiment 6The mensuration of bioavailability
Get 24 rats, body weight (205 ± 10) g, be divided at random 4 groups, wherein the cefmenoxime hydrochloride in of first group of intravenous injection embodiment 1 preparation and the compatibility mixed liquor of commercially available product sodium chloride injection (lot number: 20120801-1, Qingzhou Yaowang Pharmaceutical Co., Ltd.); The cefmenoxime hydrochloride in of second group of intravenous injection embodiment 1 preparation and the compatibility mixed liquor of commercially available product 5% glucose injection (lot number: 20121002-5, Qingzhou Yaowang Pharmaceutical Co., Ltd.); The compatibility mixed liquor of the cefmenoxime hydrochloride in of the 3rd group of intravenous injection embodiment 1 preparation and commercially available product Multiple electrolytes injection (lot number: 1206003, Kelun Pharm Ind Co., Ltd., Sichuan); The compatibility mixed liquor of the Amino Acid Compound Injection of the cefmenoxime hydrochloride in of the 4th group of intravenous injection embodiment 1 preparation and embodiment 2 preparations.Dosage is cefmenoxime hydrochloride in 1.0g and injects liquid 250ml.After administration, 2h took a blood sample 48 hours.
Adopt high performance liquid chromatography to detect the blood drug level of Abbott 50192, be specially: be filler with octadecylsilane chemically bonded silica; Take acetonitrile-water-acetic acid (10:50:1) as mobile phase; The detection wavelength is 254nm, and number of theoretical plate calculates by cefmenoxime and is not less than 2000, and the separating degree of cefmenoxime peak and adjacent impurity peaks should meet the requirements.Precision takes appropriate hydrochloric acid cefmenoxime mixed-powder (approximately being equivalent to cefmenoxime 25mg), be placed in the 25ml measuring bottle, add the 0.1mol/L phosphate buffer and (get potassium dihydrogen phosphate 6.4g, sodium hydrogen phosphate 18.9g, water 750ml dissolving is regulated pH value to 6.8 with the 1mol/L sodium hydroxide, being diluted with water to 1000ml) 5ml makes dissolving, make with the mobile phase dilution solution that every 1ml contains cefmenoxime 0.1mg, as need testing solution, precision measures 20ul injection liquid chromatography; Record chromatogram; Separately get the Abbott 50192 reference substance appropriate, measure with method, by the content of external standard method with cefmenoxime in the calculated by peak area test sample.Use software 3p87 and WT1.4 to carry out data analysis, relevant pharmacokinetic parameters result such as following table.
can be found out by above experimental data, in four assembly 5 solution, the 4th group of solution is that the compatibility mixed liquor intravenous injection of cefmenoxime hydrochloride in and the Amino Acid Compound Injection of embodiment 2 preparations of the embodiment of the present invention 1 preparation is than other three assembly, 5 mixed liquor intravenous injections, bioavailability improves greatly, proved absolutely that the present invention is with the intravenous benefit of the assembly packaging of cefmenoxime hydrochloride in and Amino Acid Compound Injection, the delayed release of xylitol, embodying of sorbefacient successful, make injection improve widely bioavailability, obtained unexpected technical effect.
Industrial applicibility
Below through the specific embodiment and the embodiment the present invention is had been described in detail; but should understand; these explanations do not consist of any restriction to scope of the present invention; in the case of without departing from the spirit and scope of protection of the present invention; can carry out multiple modification, improvement and replacement to technical solutions and their implementation methods of the present invention, these are all because falling within the scope of protection of the present invention.
Each list of references of mentioning in the application or quoting, which is hereby incorporated by reference.
Claims (2)
1. pharmaceutical composition that comprises cefmenoxime hydrochloride in and Amino Acid Compound Injection, it is characterized in that cefmenoxime hydrochloride in is Abbott 50192 and natrium carbonicum calcinatum mix homogeneously powder ampoule agent for injection, Amino Acid Compound Injection is the formulated sterile solution for injection of 18 kinds of crystalline amino acids and xylitol; Wherein, cefmenoxime hydrochloride in by the aseptic powder of Abbott 50192 and natrium carbonicum calcinatum with (C
16H
17N
9O
5S
3)
2HC1 meter 0.25-2.0g makes; Amino Acid Compound Injection is by arginine hydrochloride 2.89g, histidine monohydrochloride 2.46g, leucine 3.79g, isoleucine 1.70g, lysine hydrochloride 3.33g, phenylalanine 2.83g, threonine 1.97g, valine 1.36g, methionine 1.06g, tryptophan 0.39g, glycine 3.24g, alanine 1.88g, proline 1.00g, tyrosine 0.11g, serine 0.67g, cysteine hydrochloride 0.44g, Aspartic Acid 1.15g, glutamic acid 1.97g, sodium sulfite 0.5g, xylitol 50g, water for injection adds to 1000ml and makes.
2. pharmaceutical composition according to claim 1 is characterized in that this pharmaceutical composition can pack for Combination application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310043425.6A CN103083322B (en) | 2013-02-04 | 2013-02-04 | Medicinal composition containing injection cefmenoxime hydrochloride and compound amino acid injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310043425.6A CN103083322B (en) | 2013-02-04 | 2013-02-04 | Medicinal composition containing injection cefmenoxime hydrochloride and compound amino acid injection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103083322A true CN103083322A (en) | 2013-05-08 |
| CN103083322B CN103083322B (en) | 2014-04-16 |
Family
ID=48196804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310043425.6A Expired - Fee Related CN103083322B (en) | 2013-02-04 | 2013-02-04 | Medicinal composition containing injection cefmenoxime hydrochloride and compound amino acid injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103083322B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103393689A (en) * | 2013-08-02 | 2013-11-20 | 海南灵康制药有限公司 | Pharmaceutical composition of cefotiam hydrochloride for injection and compound amino acid injection |
| CN103446158A (en) * | 2013-09-06 | 2013-12-18 | 海南美兰史克制药有限公司 | Pharmaceutical composition of cefmenoxime hydrochloride and pediatric compound amino acid injection |
| CN103463094A (en) * | 2013-09-04 | 2013-12-25 | 海南美大制药有限公司 | Medicine composition of cefpiramide sodium and infant compound amino acid injection (19AA-I) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101439036A (en) * | 2008-12-22 | 2009-05-27 | 郑飞雄 | Pharmaceutical composition containing 18 kinds of amino acid |
| CN101569628A (en) * | 2009-06-19 | 2009-11-04 | 山东罗欣药业股份有限公司 | Cefmenoxime hydrochloride composition powder injection and manufacturing method thereof |
| CN102816174A (en) * | 2012-09-10 | 2012-12-12 | 天津市嵩锐医药科技有限公司 | Amorphous cefmenoxime hydrochloride compound |
-
2013
- 2013-02-04 CN CN201310043425.6A patent/CN103083322B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101439036A (en) * | 2008-12-22 | 2009-05-27 | 郑飞雄 | Pharmaceutical composition containing 18 kinds of amino acid |
| CN101569628A (en) * | 2009-06-19 | 2009-11-04 | 山东罗欣药业股份有限公司 | Cefmenoxime hydrochloride composition powder injection and manufacturing method thereof |
| CN102816174A (en) * | 2012-09-10 | 2012-12-12 | 天津市嵩锐医药科技有限公司 | Amorphous cefmenoxime hydrochloride compound |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103393689A (en) * | 2013-08-02 | 2013-11-20 | 海南灵康制药有限公司 | Pharmaceutical composition of cefotiam hydrochloride for injection and compound amino acid injection |
| CN103463094A (en) * | 2013-09-04 | 2013-12-25 | 海南美大制药有限公司 | Medicine composition of cefpiramide sodium and infant compound amino acid injection (19AA-I) |
| CN103446158A (en) * | 2013-09-06 | 2013-12-18 | 海南美兰史克制药有限公司 | Pharmaceutical composition of cefmenoxime hydrochloride and pediatric compound amino acid injection |
| CN103446158B (en) * | 2013-09-06 | 2015-01-07 | 海南美兰史克制药有限公司 | Pharmaceutical composition of cefmenoxime hydrochloride and pediatric compound amino acid injection |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103083322B (en) | 2014-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102552294B (en) | Compound vitamin freeze-dried powder injection for injection | |
| CN102631665B (en) | Pharmaceutical composition of alanyl glutamine injection and compound amino acid injection | |
| CN103110640B (en) | Pharmaceutical composition of injection ceftizoxime sodium and compound amino acid injection | |
| CN102429902A (en) | Pharmaceutical composition of alanyl glutamine and compound amino acid | |
| CN103083322B (en) | Medicinal composition containing injection cefmenoxime hydrochloride and compound amino acid injection | |
| CN102525963B (en) | Netilmicin sulfate lyophiled powder injection and preparation method thereof | |
| CN102274166A (en) | Medicinal composition containing ornithine aspartate | |
| CN105853441B (en) | A kind of cefoperazone sodium sulbactam sodium composition | |
| CN107519136B (en) | Succinylcholine chloride freeze-dried preparation and preparation method thereof | |
| CN102038680B (en) | Medical composition | |
| CN102335114B (en) | Stable ibuprofen arginine injection and preparation method thereof | |
| CN103393689B (en) | Pharmaceutical composition of cefotiam hydrochloride for injection and compound amino acid injection | |
| CN102961397B (en) | Pharmaceutical composition of fat emulsion injection and compound amino acid injection | |
| CN105534961B (en) | Tobramycin inhalation solution and preparation method thereof | |
| CN103446158B (en) | Pharmaceutical composition of cefmenoxime hydrochloride and pediatric compound amino acid injection | |
| CN102258507A (en) | Ibuprofen-containing pharmaceutical composition and its preparation method and application | |
| CN102008461B (en) | A kind of ibuprofen drug composite for injection | |
| CN103784438B (en) | A kind of Amino Acid Compound Injection-HBC composition and method of making the same | |
| CN103463094B (en) | Medicine composition of cefpiramide sodium and infant compound amino acid injection (19AA-I) | |
| CN103446159B (en) | Pharmaceutical composition containing pediatric compound amino acid injection and cefotiam hydrochloride | |
| CN102757471B (en) | Novel active cytidine disodium triphosphate compound and pharmaceutical composition thereof | |
| CN103446056B (en) | Pharmaceutical composition containing ceftizoxime sodium and pediatric compound amino acid injection (19AA-I) | |
| CN102698248B (en) | Medicine composition prepared from alanyl glutamine and compound amino acid by utilizing spray drying method | |
| CN102698247B (en) | Glutamine dipeptide and compound amino acid medicinal composition prepared with solvent crystallization method | |
| CN104922133A (en) | Medicine combination of cefpiramide (sodium) for injection and compound amino acid injection (18AA-V) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HAINAN SHENGXIN PHARMACEUTICAL TECHNOLOGY CO., LTD Free format text: FORMER OWNER: HAINAN ZHONGYUANTANG MEDICAL TECHNOLOGY CO., LTD. Effective date: 20140331 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 570100 HAIKOU, HAINAN PROVINCE TO: 570311 HAIKOU, HAINAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140331 Address after: 570311 Hainan city of Haikou Province Hong Kong Bamboo Development Zone Xiuying District Road No. 1, building 2, No. 1 West Patentee after: HAINAN SHENGXIN MEDICAL TECHNOLOGY CO., LTD. Address before: 570100, No. 6, No. 168, Haikou Free Trade Zone, Nanhai Avenue, Hainan, Haikou Patentee before: Hainan Zhongyuantang Medical Science & Technology Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140416 Termination date: 20170204 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |